211053-49-5

Basic information

• Product Name: 3(R)-HYDROXYMETHYLMORPHOLINE
• Synonyms: 3(R)-HYDROXYMETHYLMORPHOLINE;3(R)-HYDROXYMETHYLMORPHOLINE HCL,;(R)-3-Hydroxymethylmorpholine;(R)-morpholin-3-ylmethanol;((3R)-Morpholin-3-yl)methanol;(3R)-3-Morpholinemethanol;3(R)-Hydroxymethylmorpholine hydrochloride;(R)-3-Morpholinemethanol
• CAS NO: 211053-49-5
• Molecular Formula: C₅H₁₁NO₂
• Molecular Weight: 117.15
• Product Categories: pharmacetical;Chiral Reagents;Heterocycles
• Mol File: 211053-49-5.mol
• Article Data: 3

Chemical Properties

• Melting Point: 78-81°C
• Boiling Point: 218℃
• Flash Point: 86℃
• Appearance: White to off-white solid
• Density: 1.045
• Vapor Pressure: 0.0268mmHg at 25°C
• Refractive Index: 1.441
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform
• PKA: 14.85±0.10(Predicted)
• CAS DataBase Reference: 3(R)-HYDROXYMETHYLMORPHOLINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3(R)-HYDROXYMETHYLMORPHOLINE(211053-49-5)
• EPA Substance Registry System: 3(R)-HYDROXYMETHYLMORPHOLINE(211053-49-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 211053-49-5(Hazardous Substances Data)

Usage

Description

3(R)-HydroxyMethylMorpholine is a chiral morpholine derivative characterized by its white to off-white solid appearance. It is known for its unique chemical properties and potential applications across various industries.

Uses

Used in Pharmaceutical Industry:
3(R)-HydroxyMethylMorpholine is used as a chiral morpholine derivative for its potential applications in the development of pharmaceutical compounds. Its unique structure and properties make it a valuable component in the synthesis of various drugs and medications.
Used in Chemical Synthesis:
3(R)-HydroxyMethylMorpholine is used as a chiral morpholine derivative in chemical synthesis processes. Its specific stereochemistry allows for the creation of enantiomerically pure compounds, which is crucial in many chemical reactions and applications.
Used in Research and Development:
3(R)-HydroxyMethylMorpholine is used as a chiral morpholine derivative in research and development settings. Its unique properties make it an interesting subject for scientific studies, potentially leading to new discoveries and applications in various fields.

InChI:InChI=1/C5H11NO2/c7-3-5-4-8-2-1-6-5/h5-7H,1-4H2/t5-/m1/s1

Upstream product

• 101376-26-5 (3R)-4-benzyl-3-(hydroxymethyl)-morpholine 
• 106973-37-9 (3S)-5-oxo-4-(phenylmethyl)-3-morpholinecarboxylic acid 

Downstream Products

• 917572-35-1 {(3R)-4-[1-(diphenylmethyl)azetidin-3-yl]morpholin-3-yl}methanol 
• 441717-93-7 (R)-benzyl 3-(hydroxymethyl)morpholine-4-carboxylate 
• 1445591-28-5 (S)-benzyl 3-(tert-butoxymethyl) morpholine-4-carboxylate 
• 1445590-49-7 ((1,2-trans)-2-(5-(4-bromophenyl)-1H-imidazol-2-yl)cyclopentyl)((S)-3-(tert-butoxymethyl)morpholino)methanone 
• 1445591-33-2 (R)-benzyl 3-(methoxymethyl)morpholine-4-carboxylate 
• 696582-88-4 (R)-3-(methoxymethyl)morpholine 
• 101376-26-5 (3R)-4-benzyl-3-(hydroxymethyl)-morpholine 
• 1266238-75-8 (S)-4-benzyl-3-(fluoromethyl)morpholine 

Relevant articles and documents

A Conformational Restriction Strategy for the Identification of a Highly Selective Pyrimido-pyrrolo-oxazine mTOR Inhibitor

The mechanistic target of rapamycin (mTOR) plays a pivotal role in growth and tumor progression and is an attractive target for cancer treatment. ATP-competitive mTOR kinase inhibitors (TORKi) have the potential to overcome limitations of rapamycin derivatives in a wide range of malignancies. Herein, we exploit a conformational restriction approach to explore a novel chemical space for the generation of TORKi. Structure-activity relationship (SAR) studies led to the identification of compound 12b with a ～450-fold selectivity for mTOR over class I PI3K isoforms. Pharmacokinetic studies in male Sprague Dawley rats highlighted a good exposure after oral dosing and a minimum brain penetration. CYP450 reactive phenotyping pointed out the high metabolic stability of 12b. These results identify the tricyclic pyrimido-pyrrolo-oxazine moiety as a novel scaffold for the development of highly selective mTOR inhibitors for cancer treatment.

NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF GASTROINTESTINAL DISEASES

The application relates to new piperazine- or morpholine-substituted azetidine derivatives of formula I. These compounds are antagonists at the neurokinin receptor and can be used for the treatment of gastrointestinal diseases. The application also relate